Drug Trial Radar · NCT02791308
Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: May 29, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
587
Actual
Start
Feb 2015
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- Actavis Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 90 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety and efficacy profiles of Watson Laboratories, Inc.'s Pimecrolimus Cream, 1% to those of Valeant Pharmaceuticals North America LLC's Elidel® (pimecrolimus) Cream, 1%, and to demonstrate the superior efficacy of the two active creams over that of the placebo (Vehicle of test product), in the treatment of mild to moderate atopic dermatitis.
Conditions
- Atopic Dermatitis
Interventions
Pimecrolimus Cream 1% (Valeant)Drug
Vehicle creamDrug
Pimecrolimus Cream, 1%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Treatment Success at Visit 4/Day 15Time frame: 15 days
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
Clinical Research Center of Alabama
Birmingham, Alabama
Agave Clinical Research, LLC
Mesa, Arizona
Omni Dermatology/Physicians Research Group, LLC
Phoenix, Arizona
Northwest Arkansas Clinical Trials Center, PLLC
Rogers, Arkansas
MD Studies, Inc.
Fountain Valley, California
Alliance Research Centers
Laguna Hills, California
Medical Center for Clinical Research
San Diego, California
Skin Surgery Medical Group, Inc.
San Diego, California
Horizons Clinical Research Ctr., LLC
Denver, Colorado
Immunoe International Research Centers
Thornton, Colorado
Dermatology of Boca
Boca Raton, Florida
Olympian Clinical Research
Clearwater, Florida
International Dermatology Research, Inc.
Miami, Florida
Radiant Research, Inc.
Pinellas Park, Florida
International Clinical Research- US, LLC
Sanford, Florida
MOORE Clinical Research, Inc.
Tampa, Florida
Olympian Clinical Research
Tampa, Florida
Kansas City Dermatology PA
Overland Park, Kansas
Kentucky Pediatric/Adult Research
Bardstown, Kentucky
Dermatology Specialists Research
Louisville, Kentucky
Callender Center for Clinical Research, LLC
Glenn Dale, Maryland
David Fivenson, MD, PLC
Ann Arbor, Michigan
Minnesota Clinical Study Center
Fridley, Minnesota
MediSearch Clinical Trials
Saint Joseph, Missouri
Quality Clinical Research Inc.
Omaha, Nebraska
Karl G. Heine, MD Dermatology
Henderson, Nevada
Academic Dermatology Associates
Albuquerque, New Mexico
Pinkas E. Lebovits, MD, PC
New York, New York
Piedmont Plastic Surgery and Dermatology
Charlotte, North Carolina
Dermatology Consulting Services
High Point, North Carolina
PMG Research of Winston-Salem, LLC
Winston-Salem, North Carolina
Cyn3rgy Research
Gresham, Oregon
Baker Allergy, Asthma and Dermatology Research Center, LLC
Portland, Oregon
Asthma & Allergy Research Associates
Upland, Pennsylvania
Clinical Partners, LLC
Johnston, Rhode Island
Greenville Dermatology
Greenville, South Carolina
Spartanburg Medical Research
Spartanburg, South Carolina
ClinSearch, LLC
Chattanooga, Tennessee
Tennessee Clinical Research Center
Nashville, Tennessee
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.